Hinshaw noted that the global frequency of VITT has been estimated at roughly one case in 100,000 to 250,000 doses of the AstraZeneca vaccine.“In comparison, Albertans 50 to 59 who are diagnosed with COVID-19 are 350 times more likely to die from that infection than to experience VITT after an AstraZeneca vaccine.
They are also at least 1,500 times more likely to be hospitalized from COVID-19 than experiencing VITT after getting AstraZeneca.”Last month, Canada reported its first case of a rare blood clot in a person who had received the AstraZeneca COVID-19 vaccine.A Quebec woman who passed away in late April was the first Canadian to die of the condition after receiving the vaccine..